Expertise in
2
conditions

Elvire Tostivint-Pons

Nantes, FR 
Expertise in
2
conditions
Nantes, FR 

Overview

Elvire Tostivint-Pons practices practicing medicine in Nantes, France.

Ms. Tostivint-Pons is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer, and Small Cell Lung Cancer (SCLC).

She is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 1 clinical trial.

Gender

Female

Locations

Nantes, France
Other Locations
Toulouse, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3

61 Total Publications

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Journal: The New England journal of medicine
Published: May 29, 2026

Frequently Asked Questions about Elvire Tostivint-Pons

Is Elvire Tostivint-Pons a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Elvire Tostivint-Pons is classified as an Advanced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elvire Tostivint-Pons participate in research or clinical trials?

Yes. Elvire Tostivint-Pons has published 61 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Elvire Tostivint-Pons's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tostivint-Pons's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile